| 西妥昔单抗联合铂类药物灌注治疗胃癌致恶性腹水疗效观察 |
| |
| 引用本文： | 于榆林. 西妥昔单抗联合铂类药物灌注治疗胃癌致恶性腹水疗效观察[J]. 现代肿瘤医学, 2021, 0(13): 2300-2304. DOI: 10.3969/j.issn.1672-4992.2021.13.021 |
| |
| 作者姓名： | 于榆林 |
| |
| 作者单位： | 威海市立第三医院,山东 威海 264200 |
| |
| 基金项目： | 山东省泰安市科技发展计划项目（编号:2017NS0159） |
| |
| 摘 要： | 目的:观察西妥昔单抗联合铂类药物灌注治疗胃癌所致恶性腹水的疗效.方法:选取2015年07月至2018年06月我院接诊的胃癌恶性腹水患者100例,采用随机数表法分为两组,观察组(n=50)和对照组(n=50).对照组给予铂类药物灌注治疗,观察组在此基础上联合西妥昔单抗治疗.对比治疗后疾病控制率、腹水控制效果,记录治疗前后...
|
| 关 键 词： | 西妥昔单抗 铂类药物 灌注治疗 胃癌 恶性腹水 |
Effective observation of cetuximab combined with platinum perfusion in the treatment of malignant ascites caused by gastric cancer |
| |
| YU Yulin. Effective observation of cetuximab combined with platinum perfusion in the treatment of malignant ascites caused by gastric cancer[J]. Journal of Modern Oncology, 2021, 0(13): 2300-2304. DOI: 10.3969/j.issn.1672-4992.2021.13.021 |
| |
| Authors: | YU Yulin |
| |
| Affiliation: | Weihai Third Municipal Hospital,Shandong Weihai 264200,China. |
| |
| Abstract: | Objective:To observe the effect of cetuximab combined with platinum perfusion in the treatment of malignant ascites caused by gastric cancer.Methods:100 patients with malignant ascites of gastric cancer from July 2015 to June 2018 were selected and randomly divided into two groups:observation group (n=50) and control group (n=50).The control group was given platinum perfusion therapy,while the observation group was treated with cetuximab on this basis.The disease control rate and ascites control effect after treatment were compared.The changes of vascular endothelial growth factor (VEGF),carcinoembryonic antigen (CEA),ascites sugar chain antigen (CA199),CA125 and quality of life score before and after treatment were recorded,and the occurrence of adverse reactions was recorded.Results:After treatment,the disease control rate of the observation group was 82.00%,higher than that of the control group (64.00%,P＜0.05).After treatment,the ascites control effect of the observation group was 88.00%,higher than that of the control group (72.00%,P＜0.05).After treatment,the expression levels of vascular endothelial growth factor,CEA,CA199,CA125 and other indicators in the two groups decreased,but the expression levels of the above indicators in the observation group were lower than those in the control group (P＜0.05).After treatment,the scores of cognitive function,material life,physical function,psychological function and other quality of life indicators in the two groups increased,and the observation group was significantly higher than that in the control group (P＜0.05).During the treatment period,both groups had adverse reactions such as fatigue,fever,gastrointestinal reactions and leukopenia,but the incidence of observation group was significantly lower than that of control group (12.00% vs 30.00%) (P＜0.05).Conclusion:Cetuximab combined with platinum perfusion is effective in the treatment of malignant ascites caused by gastric cancer.It can reduce the expression of vascular endothelial growth factor and tumor markers,improve the quality of life of patients with high safety,and is worthy of clinical application. |
| |
| Keywords: | cetuximab platinum drugs perfusion therapy gastric cancer malignant ascites |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
|
